NeurAxis - יחס שווי כולל של החברה להכנסות NRXS

The replacement of opioids with non-invasive IB-Stim systems is associated with volatility, as confirmed by the enterprise value-to-sales multiple, where the indicator level is 9160.80. Qualified management with transparent testing mitigates these risks. The competitive advantage of NeurAxis, Inc. (NRXS) is based on drug-free treatment of pediatric abdominal pain, establishing a new standard in pediatrics without side effects.
NRXS (NeurAxis, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For NeurAxis, Inc. (NRXS), whose scalability depends on reducing sensor costs as volumes grow, the enterprise value-to-revenue chart reflects the market valuation of the business excluding debt load. The consolidation of this ratio signals a stabilization of market capitalization; however, a prolonged narrowing of the volatility range may foreshadow a sharp asset revaluation, creating risks of a sudden drawdown in an investor's portfolio.